Journal of Global Infectious Diseases

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 14  |  Issue : 1  |  Page : 24--30

Epitope identification and designing a potent multi-epitope vaccine construct against SARS-CoV-2 including the emerging variants


Sivasubramanian Srinivasan1, Gracy Fathima Selvaraj1, Vidya Gopalan1, Padmapriya Padmanabhan1, Kiruba Ramesh1, Karthikeyan Govindan1, Aswathi Chandran1, Prabu Dhandapani2, Kaveri Krishnasamy1, Satish Srinivas Kitambi3 
1 Department of Virology, State Viral Research and Diagnostic Laboratory (VRDL), King Institute of Preventive Medicine and Research, Chennai, Tamil Nadu, India
2 Department of Microbiology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu, India
3 Department of Translational Sciences, Institute for Healthcare Education and Translational Sciences, Hyderabad, Telengana, India

Correspondence Address:
Dr. Satish Srinivas Kitambi
Institute for Healthcare Education and Translational Sciences, 10-2-311, Plot 187, Str 4, Cama Manor, West Marredpally, Secunderabad - 500 026, Telengana
India

Introduction: The emergence of a novel coronavirus in China has turned into a SARS-CoV-2 pandemic with high fatality. As vaccines are developed through various strategies, their immunogenic potential may drastically vary and thus pose several challenges in offering immune responses against the virus. Methods: In this study, we adopted an immunoinformatics-aided approach for developing a new multi-epitope vaccine construct (MEVC). In silico approach was taken for the identification of B-cell and T-cell epitopes in the Spike protein, for MEVC various cytotoxic T-lymphocyte, helper T-lymphocyte, and B-cell epitopes with the highest affinity for the respective HLA alleles were assembled and joined by linkers. Results: The computational data suggest that the MEVC is nontoxic, nonallergenic and thermostable and elicit both humoral and cell-mediated immune responses. Subsequently, the biological activity of MEVC was assessed by bioinformatic tools using the interaction between the vaccine candidate and the innate immune system receptors TLR3 and TLR4. The epitopes of the construct were analyzed with that of the strains belonging to various clades including the emerging variants having multiple unique mutations in S protein. Conclusions: Due to the advantageous features, the MEVC can be tested in vitro for more practical validation and the study offers immense scope for developing a potential vaccine candidate against SARS-CoV-2 in view of the public health emergency associated with COVID-19 disease caused by SARS-CoV-2.


How to cite this article:
Srinivasan S, Selvaraj GF, Gopalan V, Padmanabhan P, Ramesh K, Govindan K, Chandran A, Dhandapani P, Krishnasamy K, Kitambi SS. Epitope identification and designing a potent multi-epitope vaccine construct against SARS-CoV-2 including the emerging variants.J Global Infect Dis 2022;14:24-30


How to cite this URL:
Srinivasan S, Selvaraj GF, Gopalan V, Padmanabhan P, Ramesh K, Govindan K, Chandran A, Dhandapani P, Krishnasamy K, Kitambi SS. Epitope identification and designing a potent multi-epitope vaccine construct against SARS-CoV-2 including the emerging variants. J Global Infect Dis [serial online] 2022 [cited 2022 Jul 2 ];14:24-30
Available from: https://www.jgid.org/article.asp?issn=0974-777X;year=2022;volume=14;issue=1;spage=24;epage=30;aulast=Srinivasan;type=0